These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 20657177

  • 1. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR, Ramakrishnan G, Bock HL, Lefevre I, Jacquet JM.
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [Abstract] [Full Text] [Related]

  • 2. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S, Palestroque E, De Vleeschauwer I, Han HH, Poolman J, Schuerman L, Dobbelaere K, Boutriau D.
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [Abstract] [Full Text] [Related]

  • 3. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L.
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [Abstract] [Full Text] [Related]

  • 4. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S.
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [Abstract] [Full Text] [Related]

  • 5. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, Lefevre I.
    Hum Vaccin; 2008 Mar; 4(1):60-6. PubMed ID: 18376148
    [Abstract] [Full Text] [Related]

  • 6. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
    Chatterjee S, Rego SJ, D'Souza F, Bhatia BD, Collard A, Datta SK, Jacquet JM.
    BMC Infect Dis; 2010 Oct 15; 10():298. PubMed ID: 20950457
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months.
    Riedemann S, Reinhardt G, Jara J, Rios R, Wenzel MS, Willems P, Bock HL.
    Int J Infect Dis; 2002 Sep 15; 6(3):215-22. PubMed ID: 12718838
    [Abstract] [Full Text] [Related]

  • 8. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES, Goldberg E, Hellmann S, Leibovici L.
    Cochrane Database Syst Rev; 2012 Apr 18; 2012(4):CD005530. PubMed ID: 22513932
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H, McIntyre P, Roberton D, Dinan L, Hardt K.
    Int J Infect Dis; 2010 Jan 03; 14(1):e41-9. PubMed ID: 19467896
    [Abstract] [Full Text] [Related]

  • 12. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O.
    Hum Vaccin Immunother; 2014 Jan 03; 10(10):2795-8. PubMed ID: 25483640
    [Abstract] [Full Text] [Related]

  • 13. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.
    Tregnaghi M, López P, Rocha C, Rivera L, David MP, Rüttimann R, Schuerman L.
    Rev Panam Salud Publica; 2006 Mar 03; 19(3):179-88. PubMed ID: 16640847
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, García-Martínez JA.
    Vaccine; 2003 Sep 08; 21(25-26):3593-600. PubMed ID: 12922087
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule.
    Martinón-Torres F, Salamanca de la Cueva I, Horn M, Westerholt S, Bosis S, Meyer N, Cheuvart B, Virk N, Jakes RW, Duchenne M, Van den Steen P.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2342630. PubMed ID: 38687024
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.